Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ’World Diabetes Day 2024’ together with Africa’s First Ladies, Ministries of Health, Medical Societies and Academia, through their ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Pharmaceuticals heir Frank Binder is the driving force behind 320m uber-luxury megayacht Ulyssia, which can sail anywhere ...

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...